Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mometasone furoate nasal spray clinical endpoint bioequivalence trial
CTR20231674Phase 3Completed
- Sponsor
- Zhejiang Xianju Pharmaceutical Co., Ltd.
- Start
- Jun 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of mometasone in seasonal allergic rhinitis (SAR), sponsored by Zhejiang Xianju Pharmaceutical Co., Ltd.. Started Jun 2023; status: completed.
02
Drugs
mometasone
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on CTR20231674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231674.